Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics Sep 7, 2022 08:00AM
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update Aug 11, 2022 04:05PM
Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022 Aug 2, 2022 04:05PM
Brickell Biotech (BBI) Regains Nasdaq Compliance Jul 20, 2022 08:04AM
Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement Jul 20, 2022 08:00AM
View Older Stories

Jul 6, 2022 08:00AM Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
Jul 1, 2022 02:05PM Brickell Biotech (BBI) Announces 1-For-45 Reverse Stock Split
Jul 1, 2022 02:02PM Brickell Biotech Announces 1-For-45 Reverse Stock Split
May 19, 2022 08:00AM Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
May 12, 2022 04:01PM Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 5, 2022 04:01PM Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022
May 3, 2022 04:02PM Brickell Biotech (BBI) Sells Sofpironium Bromide to Botanix Pharmaceuticals
May 3, 2022 04:02PM Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders
May 3, 2022 04:01PM Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals
Mar 15, 2022 07:30AM Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Mar 10, 2022 08:00AM Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting
Mar 8, 2022 04:05PM Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022
Feb 2, 2022 07:30AM Brickell Biotech (BBI) Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences
Feb 2, 2022 07:30AM Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences
Nov 9, 2021 04:05PM Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 1, 2021 04:05PM Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021
Oct 28, 2021 08:00AM Brickell Biotech (BBI) Prices 26.3M Share Offering at $0.38/sh
Oct 28, 2021 07:58AM Brickell Biotech Prices Public Offering of Common Stock
Oct 27, 2021 04:32PM Brickell Biotech (BBI) Announces Proposed Underwritten Public Offering of Common Stock
Oct 27, 2021 04:32PM Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock
Oct 7, 2021 06:56AM Brickell Biotech (BBI) Achieves Statistical Significance on all Primary, Secondary Endpoints from Both U.S. Phase 3 Pivotal Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis
Oct 7, 2021 06:55AM Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide G
Sep 17, 2021 08:00AM Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity
Sep 8, 2021 08:30AM Brickell Biotech to Participate at Upcoming September Conferences
Sep 1, 2021 07:05AM Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer
Sep 1, 2021 07:04AM Brickell Biotech (BBI) Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform
Sep 1, 2021 07:00AM Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases
Aug 16, 2021 08:00AM Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Aug 12, 2021 04:01PM Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Jul 29, 2021 08:00AM Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021
Jul 22, 2021 04:05PM Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter’s Option to Purchase Additional Shares
Jul 19, 2021 10:44PM Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million
Jul 19, 2021 05:26PM Brickell Biotech (BBI) Announces $5 Million Bought Deal Offering of Common Stock
Jul 19, 2021 05:25PM Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock
Jul 6, 2021 08:00AM Brickell Biotech to Participate at William Blair’s Biotech Focus Conference 2021
Jun 29, 2021 04:05PM Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Ge
Jun 24, 2021 08:00AM Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan
Jun 1, 2021 08:09AM Brickell Biotech (BBI) Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% in the Journal of Dermatology
Jun 1, 2021 08:00AM Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
May 13, 2021 04:01PM Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update
Apr 29, 2021 08:00AM Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021
Apr 27, 2021 07:36AM Brickell Biotech (BBI) Reports Complete Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel
Apr 27, 2021 07:30AM Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Apr 23, 2021 10:01AM Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis
Apr 16, 2021 10:00AM Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology
Apr 15, 2021 08:00AM Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in Dermatology
Mar 9, 2021 04:01PM Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Mar 5, 2021 08:00AM Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market
Feb 25, 2021 04:05PM Brickell Biotech to Participate in March Virtual Investor Conferences
Feb 23, 2021 04:01PM Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021
View Older Stories